Skip to main content
14 August 2026
29 August 2025

OPTEL Acquires Vanguard Robotics to Tackle Pharma Workforce Challenges

OPTEL Group, a global leader in pharmaceutical traceability and supply chain solutions, proudly announces the acquisition of Vanguard Robotics, an expert in end-of-line collaborative robot (cobot) automation. This strategic move reinforces OPTEL's commitment to innovation and positions the company at the forefront of …

28 August 2025

NWBio Expands with Advent BioServices Acquisition to Drive Growth

Northwest Biotherapeutics, Inc. a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent BioServices Ltd. from its owner, Toucan Holdings LLC. The transaction is expected to close as soon as certain legal condition…

26 August 2025

Boehringer & LEO Pharma Join Forces to Drive Innovation with SPEVIGO

Boehringer Ingelheim and LEO Pharma announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO. Under the terms of the agreement, LEO Pharma will be responsible for commercialization and further development of SPEVIGO® leveraging its global commercial platform…

26 August 2025

Pfizer Accelerates Oncology Innovation Through Global 3SBio Partnership

Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinic…

25 August 2025

Kite to Acquire Interius BioTherapeutics for $350M

Kite, a Gilead Company , announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in…

20 August 2025

AbbVie Expands Portfolio with Capstan Therapeutics Acquisition

AbbVie announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. "With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jona…

20 August 2025

XtalPi, Dong-A ST Join Forces for AI-Powered Drug Discovery

XtalPi announced that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artif…

13 August 2025

Bayer Partners with Kumquat to Advance Cancer Drug

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation an…

12 August 2025

Sartorius Invests in Nanotein for Next-Gen Immune Cell Solutions

Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. As part of the collaboration, Sartorius Stedim Biotech will invest up to 3 million US dollars in a minority sharehol…

12 August 2025

Kexing Biopharm Partners with IQVIA to Drive Global Drug Development

Kexing Biopharm has officially entered into a comprehensive strategic partnership with IQVIA, a global leader in clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. The partnership aims to accelerate the global clinical development, regulatory app…

Page 30 of 37